Cargando…
Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
OBJECTIVE: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). METHODS: Case report. RESULTS: A 53-year-old woman developed fatal influenza pneumonia associated with grade 4 lymphopenia t...
Autores principales: | Mateo-Casas, M., Reyes, S., De Trane, S., Edwards, F., Espasandin, M., Anjorin, G., Baker, D., Schmierer, K., Giovannoni, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599429/ https://www.ncbi.nlm.nih.gov/pubmed/33163633 http://dx.doi.org/10.1016/j.ensci.2020.100279 |
Ejemplares similares
-
Subcutaneous cladribine to treat multiple sclerosis: experience in
208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021) -
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021) -
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018) -
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017) -
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)